Open an account

Eton Pharmaceuticals

ETON · NASDAQ

$50.19+$0.97 (+1.97%)TodayMarket closed ·
Prev close $49.22

About ETON

Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 44 full-time employees. The company went IPO on 2018-11-09. The firm has six commercial rare disease products: INCRELEX, ALKINDI SPRINKLE, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous, and Nitisinone. INCRELEX is a biologic product used to treat pediatric patients 2 years of age and older who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). ALKINDI SPRINKLE is for the treatment of pediatric adrenocortical insufficiency. Carglumic Acid is for the treatment of hyperammonemia due to N-acetylglutamate synthase (NAGS) deficiency. Betaine Anhydrous is for the treatment of homocystinuria. Nitisinone is for the treatment of hereditary tyrosinemia type 1 (HT-1). PKU GOLIKE is a medical formula for patients with phenylketonuria (PKU). Galzin, its product, is FDA-approved for the treatment of the ultra-rare metabolic condition of Wilson Disease.

Employees
44
Headquarters
Deer Park, Illinois
Listed
Nov 9, 2018
Sector
Health Care
Industry
Pharmaceuticals
Website
etonpharma.com

ETON key statistics

Market cap
1.41B
Price-earnings ratio
126.21
Dividend yield
—
Average volume
620.87K
Volume
320.59K
Open price
$49.36
High today
$51.12
Low today
$48.88
52 Week high
$66.37
52 Week low
$14.27

Eton Pharmaceuticals (ETON) at a glance

As of Oct 20, 2026, Eton Pharmaceuticals (ETON) shares are priced at $50.19, giving the company a market cap of 1.41B and a price-to-earnings ratio of 126.21.

Today the stock has traded between $48.88 and $51.12. The current price is 2.7% above the day's low and 1.8% below its high.

Volume so far is 320.59K shares, below the average of 620.87K shares a day.

Over the past year Eton Pharmaceuticals has ranged from $14.27 to $66.37, and now sits 69% of the way up that range.

Eton Pharmaceuticals met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported $0.35 per share against an estimate of $0.1071.

The average analyst price target is $68.85, 37.2% above the current price, from 4 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 4 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 6 analystsAvg $68.85
Low
$62.62
Now
$50.19
High
$73.50

ETON earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 216.5% on average.

  1. Q3 FY24: reported $0.03 per share against an estimate of -$0.0102
  2. Q4 FY24: reported -$0.02 per share against an estimate of -$0.0034
  3. Q1 FY25: reported $0.07 per share against an estimate of $0.0544
  4. Q2 FY25: reported -$0.10 per share against an estimate of -$0.0374
  5. Q3 FY25: reported -$0.07 per share against an estimate of $0.0918
  6. Q4 FY25: reported $0.06 per share against an estimate of $0.0918
  7. Q1 FY26: reported $0.05 per share against an estimate of $0.0918
  8. Q2 FY26: reported $0.35 per share against an estimate of $0.1071

ETON news

  • Vandana Singh

    Eton Pharmaceuticals Lands Exclusive US Rights To Aquestive's Seizure Rescue Drug

  • Chandrima Sanyal

    Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach

  • Avi Kapoor

    Jim Cramer: 'You Could Make Some Money With This 5.6% Yield'

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Avi Kapoor

    Dow Falls Over 100 Points; US Consumer Sentiment Declines In August

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • Press releaseGlobe Newswire

    Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

Similar companies

Companies in the same industry as Eton Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.